Abstract: The present invention provides phospholipase substrates of the general formula: ##STR1## wherein A is an alkylene or alkenylene radical containing up to 16 carbon atoms, R is a hydrgen atom or an alkyl, alkenyl or acyl radical containing up to 20 carbon atoms or an optionally alkyl-substituted aryl or aralkyl radical containing up to 8 carbon atoms in the alkyl moiety, X is the residue of an aromatic hydroxy or thiol compound and each Y, independently of one another, is an oxygen or sulphur atom and Z is --SO.sub.3.sup..crclbar. or a radical of the general formula: ##STR2## wherein R.sup.1 can be a hydrogen atom or a radical of the general formula --(CH.sub.2).sub.n NR.sub.3.sup.2, in which n is 2, 3 or 4 and R.sup.2 is a hydrogen atom or a methyl radical, or is an inositol or serine (--CH.sub.2 --CH(NH.sub.2)--COOH) or glycerol residue.The present invention also provides a process for the optical determination of phospholipases using these substrates, as well as a reagent containing them.

Abstract: Test carrier analysis system consisting of test carriers and an associated evaluation apparatus.The evaluation apparatus has a positioning device (5) for the exact positioning of a test carrier (1). A fixing element engaging with a recess (8) of the test carrier (1) is used for this purpose.

Abstract: Thermopile has a plurality of reference junctions and a plurality of measurement thermocouple junctions connected electrically alternately in series on a dielectric support. Each reference junction has thereover a first medium which is nonthermally responsive and each measurement junction has thereover a second medium which is thermally responsive. The first and second mediums occupy areas which are arranged in a checkerboard pattern, the reference junctions under areas occupied by said first medium each being electrically connected directly to a measurement thermocouple under an area occupied by said second medium.

Abstract: The present invention is concerned with the use of aniline derivatives of the general formula: ##STR1## wherein R.sub.1 is a hydrogen atom or a lower alkyl or aryl radical, R.sub.2 is a hydrogen atom or a lower alkyl radical which can be substituted by hydroxyl, amino, carboxyl, lower alkoxycarbonyl, lower alkanoylamido, aryl lower alkyl or aryl or by a group of the structure: ##STR2## in which R.sub.5 and R.sub.6 have the meanings given hereinafter, R.sub.3 is a hydrogen or halogen atom or a carboxyl group, R.sub.4 and R'.sub.4, which can be the same or different, are hydrogen or halogen atoms, carboxyl groups or lower alkoxy radicals or lower alkyl radicals which are preferably in the m-position and R.sub.1 and R.sub.4 or R.sub.2 and R.sub.4 or R.sub.4 and R'.sub.4, when the two substituents are ortho to one another, can together form a saturated or unsaturated hydrocarbon chain containing 2 to 6 carbon atoms which can be substituted by hydroxyl or oxo groups, R.sub.

Abstract: The invention relates to a composition useful in determining an analyte in a sample. The composition contains an indicator system which forms a detectable signal in the presence of said analyte, and which is not a coupling system, as well as a pyrogallol derivative. The pyrogallol derivative causes uniform formation of detectable signal. Also described are kits useful in determining an analyte, apparatus which incorporate the composition, and a method for determining an analyte using the composition.

Abstract: An apparatus useful in analyzing samples, such as body fluids, is presented. The device is especially useful in analyzing whole blood because its configuration, with a differential vertical dimension permits rapid flow and uniform draw through the device, with contact of the relevant portion of the sample to a reagent means. Also disclosed is a method for analyzing a sample using the device.

Abstract: The present invention provides a vector for the expression of heterologous proteins in mammalian cells, wherein it contains at least one first consensus sequence is homologous to the ##STR1## in at least 10 nucleotides in total and including the first three thereof and at least one second sequence which in one of the 6th, 8th, 9th and 10th nucleotide, as well as in at least 9 nucleotides, is homologous to the sequence ##STR2## or in at least 10 nucleotides is homologous to the sequenceTATGATAATGAGor is homologous to the sequenceTGG(N).sub.6-7 GCCAA.

Abstract: A modular hip prosthesis for the replacement of a portion of the femur is provided. The prosthesis is assembled from a kit that includes a stem member having an upper portion and a lower portion, with the lower portion sized to be received in the femur. The kit also includes a body member that is sized to replace a portion of the femur and is configured to be received over the upper portion of a stem member. The kit also includes a head member that is sized to replace the head of the femur. A neck member is provided to attach the head member to the body member to form an assembled prosthesis.

Abstract: The invention involves an apparatus useful in analysis of liquid samples. At least 3 zones are provided which contain reactants which interact with the analyte and each other, leading to the detection reaction. The apparatus also has a fluid application means for reception of a liquid, and a waste zone, which absorbs excess liquid after the detection reaction has taken place. The fluid application means and waste zone are positioned at opposite ends of the apparatus.

Abstract: The present invention provides a process for the activation of gene-technologically produced, biologically active proteins expressed in prokaryotes after cell digestion by solubilization under denaturing conditions and reducing conditions and subsequent reactivation under oxidizing and renaturing conditions, wherein working is carried out at a protein concentration of 1 to 1000 .mu.g./ml. and, between the solubilization and the reactivation, a dialysis is carried out against a buffer with a pH value of from 1 to 4 containing 4 to 8 mole/liter guanidine hydrochloride or 6 to 10 mole/liter urea.

Abstract: The present invention provides a recombinant DNA, wherein it contains DNA sequences coding for the N-terminal membrane-penetrating domain of the E-protein of the phage .phi.X 174 and DNA sequences coding for the C-terminal membrane-penetrating domain of the L-protein of the phage MS2 and the DNA sequences of both phages are connected by a DNA sequence coding for a hydrophilic flexible amino acid sequence.The present invention also provides a process for the production of this recombinant DNA.Furthermore, the present invention provides for the use of the recombinant DNA and of a plasmid containing it for obtaining eukaryotic and prokaryotic metabolic products and gene-technologically produced proteins.

Abstract: A process for the preparation of S- or R-carbazole derivatives of the general formula: ##STR1## in which R is an unsubstituted or substituted amino radical and pharmacologically acceptable salts, by either reacting R-(-)-epichlorohydrin (for the S-carbozole derivative); or reacting an S-epoxide derivative of the general formula: ##STR2## in which R.sub.1 is the residue of a substituted sulphonic acid derivative (for the R-carbazole derivative); with 4-hydroxycarbazole and then with ammonia or a substituted amine of the general formula RH, and recovering the compound or converting it to a pharmacologically acceptable salt.The new R-(+)- and S(-)-carbazole derivatives provided by the inventive process have unexpected beta blocking and vasodilatory properties and are useful in pharmaceutical compositions. R-(+)-carbazole derivatives are also useful for the treatment of glaucoma.

Abstract: For the determination of fructosamine in body fluids a solution containing fructosamine and albumin is used as the standard solution for calibration which standard solution is essentially free of glucose and which has a pH between 5.0 and 6.0 and contains at least 10 mmol/l buffer.

Abstract: Pancreatic .alpha.-amylase is determined in body fluid in the presence of salivary .alpha.-amylase by combining the body fluid with a monoclonal antibody that inhibits salivary .alpha.-amylase by 95% or more and inhibits pancreatic .alpha.-amylase by 50% or less, and then detecting pancreatic .alpha.-amylase with a system for the detection of .alpha.-amylase. The monoclonal antibody may be in immobilized form. The monoclonal antibody is preferably produced by immunizing a Balb/c mouse or an AJ mouse with a specific immunogen for a specific number of times, fusing .beta.-lymphocytes obtained from the mouse with a myeloma cell line to form an antibody producing hybridoma cell line, cloning and screening the hybridoma cell line for the desired monoclonal antibody, and isolating the monoclonal antibody. The immunogen contains modified or unmodified salivary .alpha.-amylase, aluminum hydroxide and Bortadella pertussis.

Abstract: The present invention provides a test carrier for the analytical determination of a component of a sample liquid with the help of immunological reagents having a conjugate layer (2, 12), which contains a soluble conjugate of a first immunological binding partner with a labelling, a porous fixing layer (3, 13), which contains a second binding partner in carrier-fixed form binding specifically with the first binding partner, and an optical detection layer (8, 18), wherein the fixing layer (3, 13) is constructed in such a manner that the suction speed with which the liquid is transported in it is so high that the time needed for the spreading out of the liquid in the fixing layer is considerably shorter than the incubation time which is needed for the completion of the specific binding reaction between the first binding partner and the second binding partner and the optical detection layer (8, 18) is so fixed on the test carrier (1, 11) that, in a first position, it is not in contact with the fixing layer (3, 13

Abstract: The present invention provides a process for the determination of a protein according to the fluorescence polarization immunoassay principle in a homogeneous system by simultaneous incubation of the sample solution witha) a peptide sequence, labelled with a fluorescing compound, of 6 to 14 amino acids, two of which are cysteine which form a disulphide bridge with one another, the sequence thereby corresponding to an epitope sequence of the protein to be determined, andb) an antibody which is specifically bindable not only with the protein but also with the peptide sequence and displays for the fluorescing peptide sequence of the protein and the native protein molar relative affinities which differ by a factor of at most 6, and measurement of the depolarization of polarized light passed through the incubated solution.

Abstract: The present invention provides compounds of the general formula ##STR1## wherein R.sub.1 is a hydrogen atom, a methyl, ethyl, propyl, isopropyl, butyl, tert. butyl or 1-alkoxyalkyl radical or an optionally hydrophilically substituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, tetrahydropyranyl, piperidinyl, N-methyl substituted piperidinyl or N-ethyl substituted piperidinyl, pyridinyl, thiophenyl or 1,1-dioxo-tetra- hydrothiopyranyl radical or an amino group which is optionally substituted by the same or different substituents selected from methyl, ethyl, propyl and isopropyl radicals. R.sub.2 is an oligoglucoside residue with 2, 3 or 4 glucose units and X is a hydrogen atom or an optically determinable residue. The present invention also provides processes for the preparation of compounds (I) and reagents for the determination of .alpha.-amylase containing them. Furthermore, the present invention provides a process for the determination of .alpha.

Abstract: The present invention provides a method for the determination of a component of an immune reaction in a plasma sample using an immunoassay at a temperature of from 15.degree. to 40.degree. C., where one of the reactive components is in solid phase. The invention involves adding an amount of plasminogen activator sufficient to eliminate interference by fibrinogen with the component to be determined.

Abstract: The ionic strength or the specific gravity of an aqueous liquid is determined by mixing the liquid with a reagent composition which contains at least one pH buffer substance but no polyelectrolyte polymer, or at least one pH buffer substance and/or at least one complex former, determining the pH of the mixture, and evaluating the determined value.